Suchi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Revenue %
(FY 2017)
- Ebitda
- Net Worth -8.82%
(FY 2017)
- Total Assets -8.33%
(FY 2017)
About Suchi Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jitendra Giri, Rajnish Singh, and Suchita Singh serve as directors at the Company.
- CIN/LLPIN
U85191UP2015PTC069087
- Company No.
069087
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Feb 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Suchi Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajnish Singh  | Director | 20-Feb-2015 | Current |
| Jitendra Giri | Director | 20-Feb-2015 | Current |
| Suchita Singh | Director | 31-Mar-2019 | Current |
Financial Performance of Suchi Pharmaceuticals.
Suchi Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 8.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Suchi Pharmaceuticals?
In 2017, Suchi Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trimurti Rice And Flour Mills Private LimitedActive 10 years 9 monthsRajnish Singh and Suchita Singh are mutual person
- Rishambhav Green Energy Private LimitedActive 4 months 28 days
Rajnish Singh and Suchita Singh are mutual person
- Trimurti Freight Express Private LimitedActive 10 years 6 months
Rajnish Singh and Suchita Singh are mutual person
- Rishab-Sambhav Engineering & Constructions Private LimitedActive 9 years 2 months
Rajnish Singh and Suchita Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Suchi Pharmaceuticals?
Unlock and access historical data on people associated with Suchi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suchi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suchi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
